Drug Discovery 2017 Highlights 8 Key Themes in the Industry
SMi’s launches an exclusive conference on Drug Discovery, taking place on 27th & 28th March 2017 in London.
London, United Kingdom, March 10, 2017 --(PR.com)-- Bringing together industry leaders who will highlight future opportunities for novel therapeutic discovery, SMi’s inaugural conference on Drug Discovery is set to open its doors a few weeks’ time.
Some key significant themes you will explore at the two-day event:
• Pre-Clinical Aspects Of Drug Development
Includes sessions on new and novel technology such as CRISPR/Cas9, CADD and FBDD to generate tool compounds, and fragment methods for chemical biology
Presentations by: AstraZeneca, GSK, OpenEye Scientific Software, Takeda, University of York
• Target Identification
Includes sessions on structure based discovery on membrane protein targets, big data analysis, approaches to small molecule binder identification and phenotypic screening
Presentations by: leadXpro, Eli Lilly, UCB Pharma, Novartis
• Novel Technologies To Access New Chemical Matter
Includes sessions on high-content imaging, chemistry technology, expansion of chemical space using NPs and translational medicine and multi-organ-chip developments
Presentations by: Takeda, AbbVie, Sanofi, TissUse
• Protein-Based Drug Discovery And Structural Screening
Includes sessions on advancing structural information of ligand-receptor complexes, working with difficult targets and determining high-resolution structures of GPCRs
Presentations by: Merck Serono, AstraZeneca, Heptares
• Two Exclusive Post-Conference Workshops
Includes sessions on current hit-finding strategies, high throughput screening, and applications of physiochemical and biomimetic properties of molecules in early discovery
Hosted by: Sanofi, AstraZeneca, Bio-Mimeteic Chormatography Consultancy
The full agenda and list of speakers can be found on the event website.
For more details about the conference and registration information, visit www.drug-discovery.co.uk/prcom
Drug Discovery
27-28 March 2017
Holiday Inn Kensington Forum, London, UK
www.drug-discovery.co.uk/prcom
Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Matthew Apps at mapps@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Some key significant themes you will explore at the two-day event:
• Pre-Clinical Aspects Of Drug Development
Includes sessions on new and novel technology such as CRISPR/Cas9, CADD and FBDD to generate tool compounds, and fragment methods for chemical biology
Presentations by: AstraZeneca, GSK, OpenEye Scientific Software, Takeda, University of York
• Target Identification
Includes sessions on structure based discovery on membrane protein targets, big data analysis, approaches to small molecule binder identification and phenotypic screening
Presentations by: leadXpro, Eli Lilly, UCB Pharma, Novartis
• Novel Technologies To Access New Chemical Matter
Includes sessions on high-content imaging, chemistry technology, expansion of chemical space using NPs and translational medicine and multi-organ-chip developments
Presentations by: Takeda, AbbVie, Sanofi, TissUse
• Protein-Based Drug Discovery And Structural Screening
Includes sessions on advancing structural information of ligand-receptor complexes, working with difficult targets and determining high-resolution structures of GPCRs
Presentations by: Merck Serono, AstraZeneca, Heptares
• Two Exclusive Post-Conference Workshops
Includes sessions on current hit-finding strategies, high throughput screening, and applications of physiochemical and biomimetic properties of molecules in early discovery
Hosted by: Sanofi, AstraZeneca, Bio-Mimeteic Chormatography Consultancy
The full agenda and list of speakers can be found on the event website.
For more details about the conference and registration information, visit www.drug-discovery.co.uk/prcom
Drug Discovery
27-28 March 2017
Holiday Inn Kensington Forum, London, UK
www.drug-discovery.co.uk/prcom
Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Matthew Apps at mapps@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Honey de Gracia
+44 (0) 207 827 6102
www.drug-discovery.co.uk/prcom
Honey de Gracia
+44 (0) 207 827 6102
www.drug-discovery.co.uk/prcom
Contact
Categories